Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus bevacizumab as first-line therapy in PD-L1 positive advanced non-squamous non-small-cell lung cancer
ChiCTR2200056693Phase 2Not yet recruiting
- Sponsor
- Taizhou Hospital of Zhejiang Province
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab and bevacizumab in Non-small cell lung cancer (NS-NSCLC), sponsored by Taizhou Hospital of Zhejiang Province. Primary endpoint: PFS rate at 6 months. Planned start Feb 2022; status: not yet recruiting.
02
Drugs
tislelizumabbevacizumab
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on ChiCTR2200056693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056693.